ACUMEN PHARMACEUTICALS INC (ABOS) Stock Price & Overview
NASDAQ:ABOS • US00509G2093
Current stock price
The current stock price of ABOS is 2.36 USD. Today ABOS is up by 7.76%. In the past month the price decreased by -28.7%. In the past year, price increased by 141.33%.
ABOS Key Statistics
- Market Cap
- 142.945M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.01
- Dividend Yield
- N/A
ABOS Stock Performance
ABOS Stock Chart
ABOS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ABOS. When comparing the yearly performance of all stocks, ABOS is one of the better performing stocks in the market, outperforming 94.31% of all stocks.
ABOS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABOS. ABOS has a bad profitability rating. Also its financial health evaluation is rather negative.
ABOS Earnings
ABOS Forecast & Estimates
12 analysts have analysed ABOS and the average price target is 7.34 USD. This implies a price increase of 211.19% is expected in the next year compared to the current price of 2.36.
ABOS Groups
Sector & Classification
ABOS Financial Highlights
Over the last trailing twelve months ABOS reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS decreased by -17.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -98.78% | ||
| ROE | -172.28% | ||
| Debt/Equity | 0.32 |
ABOS Ownership
ABOS Latest News, Press Relases and Analysis
ABOS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.66 | 384.559B | ||
| AMGN | AMGEN INC | 15.42 | 189.672B | ||
| GILD | GILEAD SCIENCES INC | 15.77 | 173.017B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.03 | 113.435B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.53 | 81.684B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.35 | 43.88B | ||
| INSM | INSMED INC | N/A | 35.247B | ||
| NTRA | NATERA INC | N/A | 28.345B | ||
| BIIB | BIOGEN INC | 11.4 | 26.906B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.85 | 25.99B | ||
| MRNA | MODERNA INC | N/A | 20.063B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.272B | ||
| INCY | INCYTE CORP | 12.29 | 18.731B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABOS
Company Profile
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Newton, Massachusetts and currently employs 61 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
Company Info
IPO: 2021-07-01
ACUMEN PHARMACEUTICALS INC
1210-1220 Washington Street, Suite 210
Newton MASSACHUSETTS US
CEO: Daniel O'Connell
Employees: 61
Phone: 16173444190
ACUMEN PHARMACEUTICALS INC / ABOS FAQ
What does ABOS do?
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Newton, Massachusetts and currently employs 61 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
What is the stock price of ACUMEN PHARMACEUTICALS INC today?
The current stock price of ABOS is 2.36 USD. The price increased by 7.76% in the last trading session.
Does ACUMEN PHARMACEUTICALS INC pay dividends?
ABOS does not pay a dividend.
How is the ChartMill rating for ACUMEN PHARMACEUTICALS INC?
ABOS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the number of employees for ACUMEN PHARMACEUTICALS INC?
ACUMEN PHARMACEUTICALS INC (ABOS) currently has 61 employees.
Can you provide the market cap for ACUMEN PHARMACEUTICALS INC?
ACUMEN PHARMACEUTICALS INC (ABOS) has a market capitalization of 142.95M USD. This makes ABOS a Micro Cap stock.